The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Hettiarachchi SM, Thilakaratne D, Dharmasena D, Rathnapala A, Abeysinghe P, Perera E

Docetaxel-induced interstitial lung disease among patients with breast cancer: a case series and review of literature.

Respirology case reports. 2021;9(7):e00802

Taj A

Docetaxel-induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis in a patient with metastatic adenocarcinoma of the lung.

Hematology/oncology and stem cell therapy. 2013;6(3-4):117-9

Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M

Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.

Anticancer research. 2012;32(3):1103-6

Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T

Docetaxel and interstitial pulmonary injury.

Annals of oncology : official journal of the European Society for Medical Oncology. 1997;8(2):191-4